Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04365400 · ClinicalTrials.gov registry record · Phase 2

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

A Phase 2 study, sponsored by Afimmune.

Terminated
Registry status
Phase 2
Development phase
233
Enrollment target

NCT04365400: Clinical Trial Phase 2 study, sponsored by Afimmune.

NCT04365400 is a Phase 2 study that was terminated before completion, run by Afimmune. The registered enrollment target is 233 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04365400, a Phase 2 study, was terminated before completion, sponsored by Afimmune.

TERMINATED
Registry status
Phase 2
Development phase
233 participants
Enrollment target

Study Summary

To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo, in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes

Primary Outcome

Analysis of changes and percentage changes of triglycerides was performed using a Wilcoxon rank sum test with the Hodges Lehmann median and 95% confidence intervals estimates. For analysis of triglycerides, baseline was defined as the mean of the Baseline (Visit 3) and Screening 2/Week -1 (Visit 2) measurements.

Interventions

  • DRUG Placebo
  • DRUG DS102

Trial Details

FieldValue
Enrollment Target 233 participants
Start Date 2020-10-13
Est. Completion 2022-05-03
Phase Phase 2
Afimmune

3 total trials

Why NCT04365400 stopped before completion

NCT04365400 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04365400 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04365400 about?

NCT04365400 is a clinical study titled "Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes". To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo, in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes

What is the current status of trial NCT04365400?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2020-10-13. Estimated completion is 2022-05-03.

What interventions are being tested in trial NCT04365400?

The interventions under investigation include: Placebo (DRUG), DS102 (DRUG).

Who is sponsoring clinical trial NCT04365400?

This trial is sponsored by Afimmune, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04365400's enrollment target sits among peer trials

233 256th of 2000 higher than 1,745 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06993844 · 233 participants · Phase 1

    Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • NCT07141706 · 233 participants · Phase 1

    A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

  • NCT04942717 · 234 participants · NA

    Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

  • NCT05208671 · 234 participants · NA

    Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04365400, the US trial registry maintained by the National Library of Medicine. NCT04365400 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.